|  | 
| OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. | 
|  | 
|  | 
| Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; MSD; Sandoz | 
| Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline/Tesaro; MSD | 
| Speakers' Bureau - AstraZeneca; GlaxoSmithKline/Tesaro; MSD | 
| Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline/Tesaro; MSD; Roche | 
|  | 
|  | 
| Honoraria - AstraZeneca/Merck; Daiichi Sankyo; Pierre Fabre; Roche; SERVIER | 
|  | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - eXYSTAT | 
|  | 
| Consulting or Advisory Role - Abbvie; Biocodex; GenSight Biologics; Guerbet | 
|  | 
|  | 
| Honoraria - AstraZeneca; Novartis; Pfizer; Roche | 
| Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche | 
| Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche | 
|  | 
|  | 
| Consulting or Advisory Role - Clovis Oncology | 
| Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline; MSD; Roche | 
|  | 
|  | 
| Consulting or Advisory Role - AstraZeneca/Merck; Eisai; GlaxoSmithKline; MSD; PharmaMar; Roche | 
| Speakers' Bureau - AstraZeneca/Merck; GlaxoSmithKline; MSD; PharmaMar; Roche | 
| Travel, Accommodations, Expenses - Roche; Tesaro | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline | 
| Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Roche | 
| Travel, Accommodations, Expenses - AstraZeneca; Roche | 
|  | 
|  | 
| Honoraria - AstraZeneca/Merck; Clovis Oncology; GlaxoSmithKline | 
| Consulting or Advisory Role - AstraZeneca/Merck; Clovis Oncology; GlaxoSmithKline | 
| Research Funding - AstraZeneca/Merck; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; ImmunoGen; Novartis | 
| Travel, Accommodations, Expenses - GlaxoSmithKline | 
|  | 
|  | 
| Consulting or Advisory Role - AstraZeneca/Merck; BMSi; Gilead Sciences; MSD Oncology; Novartis; Sanofi | 
| Travel, Accommodations, Expenses - MSD Oncology; Roche | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck | 
| Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Novartis; Novartis; Novocure; Shattuck Labs | 
| Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst) | 
|  | 
|  | 
| Employment - AstraZeneca Canada | 
|  | 
|  | 
| Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline; Lilly; MSD; Pfizer | 
| Travel, Accommodations, Expenses - MSD; Pfizer | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Honoraria - AstraZeneca; clovis oncology; Roche; Tesaro/GSK; Tesaro/GSK | 
|  | 
|  | 
| Employment - Arcagy-Gineco | 
| Honoraria - AstraZeneca; GlaxoSmithKline | 
| Consulting or Advisory Role - AstraZeneca; Incyte; Merck; Roche | 
| Research Funding - AstraZeneca (Inst) | 
| Other Relationship - Arcagy-Gineco |